A decade after it first failed, a Shire-developed Takeda antiviral appears successful in Phase III
Nearly 20 years after it first entered the clinic and over a decade after it first flunked a Phase III trial, a Takeda-owned drug to treat CMV infections has proven effective in a late-stage study.
Takeda didn’t break down all the numbers, but said that in a 352-person trial, maribavir outperformed physician’s choice in clearing infections in transplant patients who were resistant to current treatments. In a statement, Obi Umeh, Takeda’s maribavir program leader, said they would take the data to regulators in the US and Europe.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.